---
title: Disrupting Drug Discovery From Assay Development to Lead Compound
description: High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery. In this white paper, SAMDI Tech
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![SAMDI\_DDW\_eblast banner\_1425px](https://info.edifydigitalmedia.com/hubfs/SAMDI_DDW_eblast%20banner_1425px.png "SAMDI_DDW_eblast banner_1425px")

Disrupting Drug Discovery From Assay Development to Lead Compound

 

 

 

 

*Brought to you by* 

 

![samdi\_logo\_black\_red\_DDW\_111px](https://info.edifydigitalmedia.com/hs-fs/hubfs/samdi_logo_black_red_DDW_111px.png?width=111&name=samdi_logo_black_red_DDW_111px.png)

---

 

![SAMDI\_DDW\_WP asset\_189px](https://info.edifydigitalmedia.com/hubfs/SAMDI_DDW_WP%20asset_189px.png "SAMDI_DDW_WP asset_189px")

High-throughput screening remains one of the most powerful, unbiased approaches for small molecule drug discovery.

In this white paper, SAMDI Tech CSO, Zack Gurard-Levin, discusses the important aspects to consider when choosing the right methodology for drug discovery.

Learn:

- Traditional label-dependent approaches vs. novel label-free technologies
- How researchers determine which methodology offers the most promising path forward for their target
- How to take into account assay sensitivity, data quality, costs, and speed
- When to outsource to contract research organizations with an established discovery infrastructure to lead hit identification and hit-to-lead programs

### Download the Whitepaper

## Copyright 2020 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions